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Immunotherapy and Tolerance—
Cutting Edge
In Allergology International (AI) Vol. 62 No. 4, we of-
fer a series of review articles entitled “Immunother-
apy and Tolerance - Cutting Edge”, original articles,
and letters to the editor. We believe that this issue of
the journal will be of great help for both clinical and
basic investigators working in this field.
Conventional subcutaneous injection has been the
standard practice in allergen immunotherapy since it
was first described by Dr. Noon more than 100 years
ago.1 Its efficacy and safety have been demonstrated
by a number of clinical studies, including the first
double-blind controlled trial reported by Dr.
Frankland.2 Dr. Durham has reevaluated the clinical
and mechanical significance of immunotherapy in re-
cent years from a novel point of view and has made
important contributions to this field.3-6 To introduce
this review series, Dr. Durham’s group briefly re-
views the current understanding of the efficacy and
mechanisms of immunotherapy. 7
Although conventional subcutaneous injection of
allergen extracts is still the mainstay of treatment,
sublingual immunotherapy is now recognized as an
as effective and safe alternative, especially in Europe.
Sublingual tablets are now close to market in both
the USA and Japan. Dr. Canonica has been influential
in the introduction of sublingual immunotherapy into
the clinic.8-11 Here, Dr. Canonica’s group comprehen-
sively reviews the emerging role of sublingual immu-
notherapy and discusses future directions for this ap-
proach.12
Because immunotherapy is found worldwide in al-
lergy clinics, the underlying mechanisms involved in
its use have been studied extensively. Dr. Akdis’s
laboratory, a pioneering group, studied the role of tol-
erance in subcutaneous immunotherapy against bee
venom among beekeepers.13,14 For this issue, Dr. Ak-
dis’s group presents an extensive review of the stud-
ies conducted on the mechanisms of immunotherapy
and induction of tolerance, with a discussion of poten-
tial directions for immunotherapy in the future.15
Among the eight original articles and three letters-
to-the-editor in this issue, Yokooji et al. report the
identification of the allergens in hydrolyzed wheat
proteins (HWP)-dependent exercise-induced anaphy-
laxis (WDEIA) . 16HWP-WDEIA, used in a popular
brand of facial soap, has recently become a big social
problem in Japan. Many Japanese patients with HWP-
WDEIA have the unique characteristic that they de-
velop allergic reactions following exercise after in-
gesting natural wheat products. This contrasts with
HWP-WDEIA in European patients suffering from im-
mediate allergic reactions when they eat HWP-
containing food, while they can eat normal wheat
products without problems. The authors speculate
that a specific-IgE to HWP cross-reacting with wheat
proteins exists in Japanese HWP-WDEIA patients,
finding that IgE antibodies recognizing αβ-, γ- and
ω1,2-gliadin, components of gluten, are causative al-
lergens in these patients. This is useful information
for diagnosis and desensitization therapy for HWP-
WDEIA. Ashok Kumar et al. report gene cloning of
an allergen from sapodilla whose fruits occasionally
cause oral allergy syndrome. The identified new aller-
gen, an acidic thaumatin-like protein (TLP), is ho-
mologous with other known allergic TLPs contained
in olives, grapes, kiwis, bell peppers, and tobacco.17
We appreciate all the authors for their contribu-
tions to the present issue of Allergology International.
Akio Mori
Associate Editor, Allergology International
Kenji Izuhara
Editor-in-Chief, Allergology International
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